[HTML][HTML] Current and future immunotherapeutic approaches in pancreatic cancer treatment

P Farhangnia, H Khorramdelazad, H Nickho… - Journal of Hematology & …, 2024 - Springer
Pancreatic cancer is a major cause of cancer-related death, but despondently, the outlook
and prognosis for this resistant type of tumor have remained grim for a long time. Currently, it …

[HTML][HTML] Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

L Lorenzo-Sanz, M Lopez-Cerda, V da Silva-Diz… - Nature …, 2024 - nature.com
Immune checkpoint blockade (ICB) approaches have changed the therapeutic landscape for
many tumor types. However, half of cutaneous squamous cell carcinoma (cSCC) patients …

Targeting the deubiquitinase USP2 for malignant tumor therapy

S Zhang, Y Guo, S Zhang, Z Wang… - Oncology …, 2023 - spandidos-publications.com
The ubiquitin‑proteasome system is a major degradation pathway for> 80% of proteins in
vivo. Deubiquitylases, which remove ubiquitinated tags to stabilize substrate proteins, are …

Shaping of Vector Beams Based on Caustic Design

S Liu, Z Zeng, X Tong, P Xu… - Laser & Photonics …, 2024 - Wiley Online Library
Appropriate wavefront design can endow light fields with many useful properties, such as
accelerating, anti‐diffracting, self‐healing, and the capability to exhibit customizable …

Exogenous HMGB1 promotes pancreatic cancer progression by supporting the crosstalk between tumor and myeloid-derived suppressor cell

F Wang, W Wei, T San, L Li - 2024 - researchsquare.com
Background The main reasons pancreatic cancer (PC) is difficult to treat are high tissue
fibrosis and a strong immunosuppressive microenvironment. Therefore, it is necessary to …